A current opinion on the safety and efficacy of doxycycline including parenteral administration – A review
More details
Hide details
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Warmia and Mazury in Olsztyn, Poland
Michał Majewski   

Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Warmia and Mazury in Olsztyn, Żołnierska 14 C, 10-561 Olsztyn, Poland. Tel.: +48 89 524 61 88; fax: +48 89 524 61 88.
Submission date: 2013-10-03
Acceptance date: 2013-12-05
Online publication date: 2014-04-26
Publication date: 2020-03-26
Pol. Ann. Med. 2014;21(1):57–62
Doxycycline was introduced into medical practice over 40 years ago but because of increasing bacterial resistance its value has decreased. It remains, however, the treatment of choice for infections caused by atypical organisms such as chlamydia, rickettsia, brucella and the spirochete. Recent studies indicate other possible benefits.

The aim of this study was to present the pharmacological characteristic of doxycycline antibiotic focusing on parenteral administration.

Material and methods:
The attempt was made to characterize thoroughly doxycycline antibiotic and its effect on human health. Using keywords ‘‘doxycycline,’’ ‘‘vibramycin,’’ ‘‘parenteral injection,’’ ‘‘atypical bacteria’’ we performed a review of relevant mainly English articles based on a Medline search before May 2013, focusing on last five years.

Doxycycline is primarily used in the treatment of infections of the upper and lower respiratory tract, as well as with gastrointestinal and sexually transmitted diseases. Furthermore, anti-inflammatory and immunomodulatory properties of doxycycline were found, which enable this medication to be used in the treatment of serious diseases, often with an immunological background or prophylactically, as a protective agent against the development of excessive inflammation in the human body. Moreover an anticancer effect of doxycycline has been described.

Currently, doxycycline is rarely used, mainly because of the presence of a high percentage of drug-resistant strains of bacteria. However, there is a group of infections, in which the antibiotic has not lost its therapeutic value and is still the first choice. The additional advantage is the beneficial effect on the human immune system. Further studies are indicated, to confirm the effectiveness of doxycycline in the treatment of various cancers.

None declared.
British National Formulary 66. London: BMJ Publishing & RPS Publishing; 2013.
Rekomendacje Polskiego Towarzystwa Ginekologicznego w zakresie zakażeń przenoszonych drogą płciową w położnictwie i ginekologii. Rekomendacje Polskiego Towarzystwa Ginekologicznego, 2003–2007 [Polish Gynecological Society Recommendations in the field of sexually transmitted infections in obstetrics and gynecology. Polish Gynecological Society Recommendations 2003–2007]. Ginekol Dypl. 2008;1:2013–2018.
WHO. Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances. 2009. [accessed 02.12.2013].
WHO. International Nonproprietary Names Modified. 2006. [accessed 02.12.2013].
The European Pharmacopoeia. 7th ed. 2010.
WHO. The International Pharmacopoeia. 4th ed. 2006. [accessed 02.12.2013].
The Japanese Pharmacopoeia. 15th ed. (JP XV) Japan: Pharmaceuticals and Medical Devices Agency; 2006. [accessed 02.12.2013].
Martindale: The Complete Drug Reference. Electronic Version. Medicines Complete. 2006. http://www.medicinescomplete.c... [accessed 02.12.13].
Vargas-Estrada D, Gracia-Mora J, Sumano H. Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves. Res Vet Sci. 2008;84(3):477–482.
Katzung B, Masters S, Trevor A. Basic and Clinical Pharmacology. 12th ed. New York: McGraw-Hill Medical Publishing Division; 2012.
WHO. Model Lists of Essential Medicines. 15th ed. 2007. http:// [accessed 02.12.2013].
U.S. Food and Drug Administration, Department of Health and Human Services, Center for Devices and Radiological Health. Title 21 – Food and Drugs. Chapter I – Subchapter D – Drugs for Human Use. Part 320 – Bioavailability and Bioequivalence Requirements. Food and Drug Administration; 2012. [accessed 02.12.2013].
Batty KT, Law AS, Stirling V, et al. Pharmacodynamics of doxycycline in a murine malaria model. Antimicrob Agents Chemother. 2007;51(12):4477–4479.
Dahl EL, Shock JL, Shenai BR, et al. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006;50(9):3124–3131.
Sagar J, Sales K. Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria. Cancer Cell Int. 2010;10–31.
Carrascosa MF, Lucena MI, Andrade RJ, et al. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clin Ther. 2009;31(5):1014–1019.
Kozera-Ptaszyńska U, Fornal M, Grodzicki T. Porównanie leczenia empirycznego pozaszpitalnego zapalenia płuc z zastosowaniem monoterapii (amoksycylina z kwasem klawulanowym) i leczenia skojarzonego (amoksycylina z kwasem klawulanowym w połączeniu z doksycykliną) [Comparison of monotherapy (amoxicillin–clavulanate) and dual therapy (amoxicillin–clavulanate plusdoxycycline) in treatment of community-acquired pneumonia]. Gerontol Pol. 2006;14(4):190–194.
Hryniewicz W, Kadłubowski M, Skoczyńska A. Dane Krajowego Ośrodka Referencyjnego ds. Lekowrażliwości Drobnoustrojów. [Data from The Polish Committee on Antimicrobial Susceptibility Testing]. Narodowy Instytut Zdrowia Publicznego [National Institute of Public Health]; 2006. [accessed 02.12.2013].
Ludlam HA, Enoch DA. Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK? Int J Antimicrob Agents. 2008;32(2):101–105.
Rhee DJ, Colby KA, Rapuano CJ, et al. Ophthalmologic Drug Guide. 2nd ed. New York: Springer Science Business Media, LLC; 2011.
Mayor MT, Roett MA, Uduhiri KA. Diagnosis and management of gonococcal infections. Am Fam Physician. 2012;86(10):931–938.
Owczarek W, Wydrzyńska A, Paluchowska E. Antybiotykoterapia w chorobach skóry [Antibiotic therapy in skin diseases]. Pol Merk Lek. 2011;30(179):367–372.
Oyston PC, Williamson ED. Prophylaxis and therapy of plague. Expert Rev AntiInfect Ther. 2013;11(8):817–829.
Galanakis E, Bitsori M. Rickettsioses in children: a clinical approach. Adv Exp Med Biol. 2011;719:145–162.
Jahnz-Różyk K, Targowski T, Jurkiewicz D, et al. Bakterie atypowe w zakażeniach dróg oddechowych – patogeneza i diagnostyka [Atypical bacteria in respiratory tract infections – pathogenesis and diagnosis]. Pol Merk Lek. 2008;25(149):412–414.
Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, et al. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012.
Suliburska J. Interakcje doksycykliny z pożywieniem [Doxycycline and food interactions]. Farm Współcz. 2011;4:83–84.
McIver SR, Muccigrosso MM, Haydon PG. The effect of doxycycline on alcohol consumption and sensitivity: consideration for inducible transgenic mouse models. Exp Biol Med (Maywood). 2012;237(10):1129–1133.
Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf. 2008;7(5):571–577.
Lau B, Mutyala D, Dhaliwal D. A case report of doxycyclineinduced Stevens–Johnson syndrome. Cornea. 2011;30(5):595–597.
Rote-Liste. Arzneimittelsverzeichnis fur Deutschland (einschließlich EU-Zulassungen und bestimmterMedizinprodukte). Rote Liste Service GmbH; 2007. [accessed 02.12.2013].